caa a22 4500 477071198 CHVBK 20180405111426.0 cr unu---uuuuu 170330e19960801xx s 000 0 eng 10.1007/BF01691158 doi (NATIONALLICENCE)springer-10.1007/BF01691158 Methods of measuring susceptibility of anaerobic bacteria to trovafloxacin, including quality control parameters [Elektronische Daten] [A. Barry, P. Fuchs, C. Thornsberry, J. McLaughlin, S. Jenkins, D. Hardy, S. Allen] Three methods approved by the National Committee for Clinical Laboratory Standards for testing the susceptibility of anaerobic bacteria were used to evaluate the fluoroquinolone, trovafloxacin. The methods gave essentially comparable results with 126 anaerobes and with three quality control strains. A collaborative study defined the quality control range for trovafloxacin MICs. Trovafloxacin had good in vitro activity against the more common anaerobes (MIC 90 <- 2.0 (Μg/ml). Trovafloxacin (CP-99,219) is a fluoroquinolone with a broad spectrum of antibacterial activity (1-3). Its in vitro spectrum includes many anaerobic bacteria (4).The National Committee for Clinical Laboratory Standards (NCCLS) currently recommends three different methods for testing the susceptibility of anaerobic bacteria (5). The standard reference method is an agar dilution procedure using Wilkins-Chalgren agar. Two alternative methods are an agar dilution technique using Brucella blood agar and a microdilution procedure using a broth version of Wilkins-Chalgren medium. It is important to determine whether these three procedures actually produce identical test results with each antimicrobial agent likely to be tested against anaerobes. Springer-Verlag, 1996 Barry A. The Clinical Microbiology Institute, P.O. Box 947, 97062, Tualatin, Oregon, USA aut Fuchs P. The Clinical Microbiology Institute, P.O. Box 947, 97062, Tualatin, Oregon, USA aut Thornsberry C. Microbiology Reference Laboratory, 37064, Franklin, Tennessee, USA aut McLaughlin J. University of New Mexico, 87106, Albuquerque, New Mexico, USA aut Jenkins S. Florida University Medical Center, 32209, Jacksonville, Florida, USA aut Hardy D. University of Rochester, 14642, Rochester, New York, USA aut Allen S. Indiana University Medical Center, 46202, Indianapolis, Indiana, USA aut European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/8(1996-08-01), 676-678 0934-9723 15:8<676 1996 15 10096 https://doi.org/10.1007/BF01691158 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01691158 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Barry A. The Clinical Microbiology Institute, P.O. Box 947, 97062, Tualatin, Oregon, USA aut NATIONALLICENCE 700 1- Fuchs P. The Clinical Microbiology Institute, P.O. Box 947, 97062, Tualatin, Oregon, USA aut NATIONALLICENCE 700 1- Thornsberry C. Microbiology Reference Laboratory, 37064, Franklin, Tennessee, USA aut NATIONALLICENCE 700 1- McLaughlin J. University of New Mexico, 87106, Albuquerque, New Mexico, USA aut NATIONALLICENCE 700 1- Jenkins S. Florida University Medical Center, 32209, Jacksonville, Florida, USA aut NATIONALLICENCE 700 1- Hardy D. University of Rochester, 14642, Rochester, New York, USA aut NATIONALLICENCE 700 1- Allen S. Indiana University Medical Center, 46202, Indianapolis, Indiana, USA aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/8(1996-08-01), 676-678 0934-9723 15:8<676 1996 15 10096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer